Browse

Prevalence of Helicobacter hepaticus, Murine Norovirus, and Pneumocystis carinii and Eradication Efficacy of Cross-Fostering in Genetically Engineered Mice

DC Field Value Language
dc.contributor.authorYeom, Su-Cheong-
dc.contributor.authorYu, Sun-A-
dc.contributor.authorChoi, Eun-Young-
dc.contributor.authorLee, Byeong-Chun-
dc.contributor.authorLee, Wang-Jae-
dc.date.accessioned2012-07-09T06:36:15Z-
dc.date.available2012-07-09T06:36:15Z-
dc.date.issued2009-10-
dc.identifier.citationEXPERIMENTAL ANIMALS; Vol.58, No.5; 497-504ko_KR
dc.identifier.issn1341-1357-
dc.identifier.urihttp://hdl.handle.net/10371/78660-
dc.description.abstractWe investigated the prevalence of Helicobacter hepaticus, murine norovirus (MNV), and Pneumocystis carinii and the efficacy of cross-fostering for their eradication in 49 genetically engineered mouse (GEM) strains at our institute. Prevalences of H. hepaticus, MNV, and P. carinii were 33.9, 36.5, and 8.6%, respectively, and immunodeficient strains showed relatively higher prevalence of the 3 pathogens than immunocompetent strains. Additionally, the same immune phenotype strains showed similar prevalences. Furthermore, it was found that NKT cells might play a role in H. hepaticus resistance. Interestingly, there was a high incidence of H. hepaticus and MNV multiple infection. Strains with single or multiple infections of H. hepaticus, MNV, and/or P carinii were selected, and cross-fostering was conducted. Cross-fosterings were successful at eradicating P carinii, but there were some failures for H. hepaticus and MNV, and the efficacy of eradication was relatively low compared with previous studies. We thought that this low efficacy might have been due to persistent infection and the high suscepibility to H. hepaticus and MNV of immunodeficient GEM strains. Therefore, cross-fostering may be appropriate for P. carinii eradication, but be inappropriate for repopulation of a new breeding colony with H. hepaticus or MNV infected GEM strains. Our findings provide basic data on maintenance, strain susceptibility, and successful rederivation, especially for GEMs.ko_KR
dc.language.isoenko_KR
dc.publisherINT PRESS EDITING CENTRE INCko_KR
dc.subjectcross-fosteringko_KR
dc.subjectprevalenceko_KR
dc.subjectPneumocystis cariniiko_KR
dc.subjectHelicobacter hepaticusko_KR
dc.subjectmurine norovirusko_KR
dc.titlePrevalence of Helicobacter hepaticus, Murine Norovirus, and Pneumocystis carinii and Eradication Efficacy of Cross-Fostering in Genetically Engineered Miceko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor염수청-
dc.contributor.AlternativeAuthor유선아-
dc.contributor.AlternativeAuthor최은영-
dc.contributor.AlternativeAuthor이병춘-
dc.contributor.AlternativeAuthor이왕재-
dc.identifier.doi10.1538/expanim.58.497-
dc.citation.journaltitleEXPERIMENTAL ANIMALS-
dc.description.citedreferenceLencioni KC, 2008, COMPARATIVE MED, V58, P522-
dc.description.citedreferenceHenderson KS, 2008, LAB ANIMAL, V37, P314-
dc.description.citedreferenceNagamine CM, 2008, INFECT IMMUN, V76, P2758, DOI 10.1128/IAI.01604-07-
dc.description.citedreferenceCompton SR, 2008, J AM ASSOC LAB ANIM, V47, P25-
dc.description.citedreferenceGuo L, 2008, VACCINE, V26, P460, DOI 10.1016/j.vaccine.2007.11.039-
dc.description.citedreferenceKostomitsopoulos N, 2007, LAB ANIMAL, V36, P37-
dc.description.citedreferenceMumphrey SM, 2007, J VIROL, V81, P3251, DOI 10.1128/JVI.02096-06-
dc.description.citedreferenceKerton A, 2006, LAB ANIM-UK, V40, P115, DOI 10.1258/002367706776319033-
dc.description.citedreferenceBohr URM, 2006, J CLIN MICROBIOL, V44, P738, DOI 10.1128/JCM.44.3.738-742.2006-
dc.description.citedreferenceWard JM, 2006, TOXICOL PATHOL, V34, P708, DOI 10.1080/01926230600918876-
dc.description.citedreferenceFranklin CL, 2006, ILAR J, V47, P141-
dc.description.citedreferenceCrisler-Roberts R, 2005, COMPARATIVE MED, V55, P515-
dc.description.citedreferenceWatson J, 2005, COMPARATIVE MED, V55, P465-
dc.description.citedreferenceMaurer KJ, 2005, GASTROENTEROLOGY, V128, P1023, DOI 10.1053/j.gastro.2005.01.008-
dc.description.citedreferenceSeoki S, 2005, EXP ANIM TOKYO, V54, P85, DOI 10.1538/expanim.54.85-
dc.description.citedreferenceVan Keuren ML, 2004, TRANSGENIC RES, V13, P363, DOI 10.1023/B:TRAG.0000040040.82536.a5-
dc.description.citedreferenceLivingston RS, 2004, COMPARATIVE MED, V54, P301-
dc.description.citedreferenceMyles MH, 2003, INFECT IMMUN, V71, P3885, DOI 10.1128/IAI.71.7.3885-3893.2003-
dc.description.citedreferenceSingletary KB, 2003, COMPARATIVE MED, V53, P259-
dc.description.citedreferenceAn CL, 2003, INFECT IMMUN, V71, P2065, DOI 10.1128/IAI.71.4.2065-2070.2003-
dc.description.citedreferenceKarst SM, 2003, SCIENCE, V299, P1575-
dc.description.citedreferenceEngle SJ, 2002, CANCER RES, V62, P6362-
dc.description.citedreferenceFuruta T, 2001, J EUKARYOT MICROBIOL, p129S-
dc.description.citedreferenceGoto K, 2000, CURR MICROBIOL, V41, P161, DOI 10.1007/s002840010111-
dc.description.citedreferenceTruett GE, 2000, COMPARATIVE MED, V50, P444-
dc.description.citedreferenceWhary MT, 2000, COMPARATIVE MED, V50, P436-
dc.description.citedreferenceMacy JD, 2000, COMPARATIVE MED, V50, P49-
dc.description.citedreferenceKullberg MC, 1998, INFECT IMMUN, V66, P5157-
dc.description.citedreferenceLi XT, 1998, INFECT IMMUN, V66, P5477-
dc.description.citedreferenceWhary MT, 1998, INFECT IMMUN, V66, P3142-
dc.description.citedreferenceFoltz CJ, 1998, HELICOBACTER, V3, P69-
dc.description.citedreferenceSHAMES B, 1995, J CLIN MICROBIOL, V33, P2968-
dc.description.citedreferenceWARD JM, 1994, J NATL CANCER I, V86, P1222-
dc.description.citedreferenceBECK JM, 1991, AM J RESP CELL MOL, V5, P186-
dc.description.citedreferenceROTHS JB, 1990, AM J PATHOL, V136, P1173-
dc.description.tc4-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Anatomy (해부학전공)Journal Papers (저널논문_해부학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse